Shattuck Shifts Gears After Lackluster CD47-Targeting Bispecific Results

The biotech is cutting jobs and discontinuing development of its anti-CD47 bispecific for blood cancers and moving its focus to SL-325, which targets the TL1A-DR3 axis in autoimmune diseases.

• Source: Shutterstock

Shattuck Labs, Inc. is moving to focus its clinical efforts on autoimmune diseases with SL-325 after deciding to discontinue its hematology-oncology candidate, SL-172154, due to efficacy that did not reach a high enough bar for overall survival (OS) improvement. The decision marks a strategic shift for the company, which includes a 40% reduction in its workforce, but also yet another blow for the once-promising field of CD47-directed cancer immunotherapies.

The biotech said 1 October that it would discontinue development of SL-172154, a CD47xCD40L-directed bispecific antibody, in TP53-mutated acute myeloid...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D